Behavioral disturbances in Parkinson's disease by Anderson, Karen E.
arkinson’s disease (PD) is now being recog-
nized as a complex illness with numerous behavioral
symptoms, in addition to the well-recognized motor
symptoms such as tremor, rigidity, postural instability,
and bradykinesia. Depression, anxiety, psychosis, and
cognitive changes are all extremely common in PD.The
magnitude of these symptoms in PD has been revealed
by several large studies of patients with PD.Over half of
all PD patients experience psychiatric illness at some
point in the disease. Depression and hallucinations are
the most commonly described psychiatric symptoms,but
many others occur.Studies have shown that psychiatric
symptoms are often unrecognized in PD patients by
their physicians and—when they are recognized—often
go undertreated. Specific cognitive deficits have been
described in early PD,and at least a third of PD patients
develop dementia. Surgical procedures to treat motor
symptoms are also increasingly being implicated as a
cause of behavioral changes,both positive and negative,
in patients with PD.
Mood disorders
Depression has been shown to occur more often in
patients with PD than in age-matched samples.
1 Reports
of prevalence of depression in PD have varied widely,
depending on how the diagnosis of depression is made.
Reviews of prior work indicate that about 40% of PD
patients are depressed.These studies may not fully repre-
sent the frequency of depression,however,since most were
based on information gathered from patients in clinics.
Scott et al
2 examined a sample of 948 patients and found
that 36% of PD patients complained of depression.
However,depression was not identified by the patients as
the most distressing symptom.A population-based study
of 97 PD patients found that 36.1% reported mild depres-
sive symptoms,while another 10% reported moderate and
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Treatment of Parkinson’s disease (PD) is complex and often
involves addressing behavioral changes in addition to the
movement disorder. Patients with PD are susceptible to
any psychiatric condition seen in the general population;
some disorders, such as depression and anxiety, may result
from PD-related neuropathological changes. Medication-
related hallucinations are seen in many PD patients who
are treated with dopaminergic agents for motor symp-
toms. Cognitive impairment is also seen and can be multi-
factorial. Treatment of behavioral symptoms in PD can
greatly improve patients’ overall function and quality of
life. As surgical interventions to treat motor symptoms,
such as deep brain stimulation of the subthalamic nucleus
of the substantia nigra, become more prevalent, the
behavioral effects of these procedures must also be
addressed.  
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3 In a small, community-based New
Zealand study, the prevalence of major depression was
2.7%;overall prevalence of mood and anxiety disorders
was 6.8% in nondemented PD patients.The prevalence of
mental illness for these PD patients did not differ signifi-
cantly from that of age-matched controls with no neuro-
logical disease,but similar disability.
4 Rojo et al
5 estimated
the prevalence of depressive symptoms,as related to other
clinical data,in a series of 350 PD patients over a 9-year
period.Mild-to-moderate depressive symptoms and severe
depressive symptoms were found in 40.2% and 16.7% of
PD patients,respectively.Female gender,advanced dis-
ease,and poorer cognitive performance were significantly
associated with depressive symptoms.On follow-up,34%
of patients remained stable,35% showed an improvement
in depressive symptoms,and 30.9% worsened.
In addition to reactive mood changes due to loss of func-
tion,neurochemical changes in PD probably contribute
to the development of mood symptoms. Loss of the
dopamine neurons in the ventral tegmental area,the ori-
gin of mesolimbic dopaminergic projection,is the most
likely neuropathological cause of mood symptoms in PD,
since changes in the serotonin and norepinephrine sys-
tems are not as extensive. Although one earlier study
found lower levels of serotonin metabolites in PD
patients with major depression compared to those with-
out,
6 most cerebral spinal fluid (CSF) studies did not con-
cur with this result.
7-9 However,positron emission tomog-
raphy (PET) has shown hypometabolism in caudate and
inferior orbitofrontal cortex in depressed PD patients,
possibly indicating damage to the dopaminergic system
from the ventral tegmental region.
10 Other blood flow
studies of major depression in PD found changes in
medial frontal cortex and the anterior cingulate.
11These
changes seen in PD depression are similar to those seen
in some studies of major depression.
A study of major depression and dysthymia in 78 PD
patients with classic PD (tremor plus rigidity and/or
bradykinesia) compared with 34 akinetic-rigid variant
PD patients found that the prevalence of dysthymia was
similar in the two groups (31% versus 32%,respectively).
However,the finding for major depression was signifi-
cantly different,with akinetic-rigid variant patients show-
ing a higher prevalence of major depression compared
with the classic variant patients (38% versus 15%,respec-
tively). Bradykinesia was the motor symptom most
highly correlated with severity of depression.The authors
suggest that the pattern of neurodegeneration may dif-
fer in akinetic-rigid parkinsonism,such that frontal lobe
circuits are more affected compared with classic PD.
12
The effect of “on”and “off”medication fluctuations on
mood and anxiety symptoms has also been studied.
Maricle et al
13 found improvement in mood and anxiety
along with motor function after levodopa administration,
compared with placebo.
Treatment of depression in patients with PD is generally
the same as that for any elderly person,with lower doses
of medication and heightened awareness of medication
interactions and side effects (Table I).Work by Shulman
et al
14 and Weintraub et al
15 suggests that depression in PD
is often unrecognized by physicians,and that when treat-
ment is attempted, it is often suboptimal. Few double-
blind,placebo-controlled studies have been conducted on
the treatment of depression in PD.A meta-analysis by
Klassen et al
16 found a total of 12 well-designed,placebo-
controlled,double-blind studies of antidepressant efficacy
in PD in the literature,all of which were with tricyclic anti-
depressants (TCAs).Dry mouth and orthostatic hypoten-
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Table I. Examples of treatment for depressed mood in Parkinson’s disease. SSRI, selective serotonin reuptake inhibitor; SNRI, selective noradrenaline
reuptake inhibitor; TCA, tricyclic antidepressant. 
Class Example(s) Average dose  Starting dose Comments
(mg/day) (mg/day)
SSRI Escitalopram 10 10 All may also be used for treatment of anxiety;
Paroxetine 20 10 higher doses may be needed if anxiety
Sertraline 50-100 25 is the main target symptom.
SNRI Venlafaxine 37.5-150 37.5 Useful for both depression and anxiety
TCA Nortriptyline 50-150 25 Monitor blood levels for therapeutic range; 
nighttime dosing suggested, since can be sedating
Other Bupropion 100-300 100 Bupropion may be activating, can worsen anxiety 
Mirtazapine 15-45 15 Mirtazapine can be very sedating, helpful if depression 
accompanied by insomnia and/or agitationsion were the most commonly seen side effects of TCAs.
PD patients may also develop constipation,urinary reten-
tion,blurred vision,and unwanted sedation on these med-
ications.In extreme cases,delirium may occur.A placebo-
controlled trial of the selective serotonin reuptake
inhibitor (SSRI) citalopram for depression in PD found
that Hamilton Depression Scale scores decreased in both
the citalopram-treated and the placebo-treated groups of
PD patients.
17 The authors questioned the use of the
Hamilton Depression Scale for evaluation of mood
changes in PD.No exacerbation of motor symptoms was
seen in the citalopram treatment group compared with the
placebo group.Chung et al,
18 in their systematic review of
efficacy and safety of antidepressant treatment in PD,con-
cluded that there are insufficient data on the efficacy and
safety of antidepressant therapies in PD,and that treat-
ment recommendations could not be definitively made at
this time.One particular potential drug interaction should
be noted. The manufacturer of selegiline has advised
against its use with antidepressants,due to concern regard-
ing the possible overstimulation of the serotonin system,
leading to the serotonin syndrome.However,the risk of
serotonin syndrome has been very low in clinical experi-
ence with these medications.
Noncontrolled studies and case reports suggest that
SSRIs are helpful in treatment of depression and other
psychiatric conditions in PD,and have no adverse effects
on motor symptoms
19;other reports indicate that motor
symptoms may worsen with SSRI use, although this
effect is reversible with discontinuation of the SSRI.
20
Dell’Agnello et al
21 used an open-label study to assess the
efficacy of four SSRIs (citalopram,fluoxetine,fluvoxam-
ine, and sertraline) for treatment of depression in PD
patients.In their study of 62 patients,all four SSRI treat-
ment groups showed significant improvement in depres-
sive symptoms without worsening motor symptoms.
Bupropion, an antidepressant with dopamine agonist
effects,has received little study in PD to date.It produced
dose-limiting side effects in some subjects in the limited
investigations that have been conducted with PD
patients.
22There are currently no studies on the efficacy
of psychotherapy for treatment of depression in PD.
Anxiety disorders
Anxiety disorders (including generalized anxiety, social
phobia,obsessive-compulsive disorder,and panic disorder)
are probably increased in PD,although there has been lit-
tle research in this area.Many PD patients have anxiety
symptoms due to legitimate concern about their chronic,
progressive illness.In the small studies that have been con-
ducted to date,PD patients also had higher rates of anxi-
ety disorders compared with other neurological
23,24 and
medical illnesses.
25 One study found actual anxiety disor-
ders,separate from simple anxiety symptoms,interfered
with normal function in 40% of patients with PD.
26Anxiety
disorders are often seen in conjunction with depression in
PD, a common comorbidity in the general population.
27
Anxiety symptoms may occur with “on-off”fluctuations in
medication treatment of motor symptoms.
28,29
There is some evidence that anxiety disorders in PD are
linked to the underlying neurobiology of the illness.
Noradrenergic dysfunction is implicated most strongly in
studies of anxiety disorders in the general population,
and noradrenergic dysfunction may play a role in devel-
opment of anxiety symptoms in PD.Neuropathological
changes in the noradrenergic system,including cell loss
in the locus ceruleus,have been seen in PD brain autopsy
studies.
30 In a preliminary yohimbine challenge study,
Richard et al
31 administered oral yohimbine,an α2-adren-
ergic autoreceptor blocker,to 6 PD patients with anxiety
or depression,2 PD patients with no psychiatric symp-
toms,and 2 normal controls.The patients with a history
of anxiety showed precipitation of panic attacks follow-
ing the challenge at a rate similar to that seen in anxiety
disorder patients given yohimbine.All the PD patients
showed increased sensitivity to development of somatic
symptoms following yohimbine challenge. This study,
while too small to offer any conclusive evidence, does
suggest that there are noradrenergic system alterations
in PD mimicking those thought to occur in primary anx-
iety disorders. Further work is obviously needed to 
investigate noradrenergic dysfunction in PD. Deficits 
in both the serotonergic and GABAergic (GABA,
γ-aminobutyric acid) systems have also been implicated
in the development of anxiety disorders, and PD has
been reported to affect both systems.
32,33
Some characteristics of anxiety disorders seen in PD are
different from those seen in the general population,fur-
ther suggesting a link to the neuropathology of PD.There
is no gender discrepancy in anxiety disorders in PD,
28
unlike the higher prevalence of female anxiety disorder
patients in the general population.Development of anxi-
ety disorders in PD typically occurs after onset of motor
symptoms.
28,34This is also in contrast to anxiety disorders
in the general population,which usually begin early in life.
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35 examined the prevalence of general-
ized anxiety,generalized anxiety disorder,panic attacks,
and panic disorder in PD and in primary dystonia.
Generalized anxiety disorder was more common in dys-
tonia patients,while panic disorder was more common in
those with PD. Generalized anxiety developed more
commonly after dystonia onset, while panic attacks
developed more commonly after onset of PD. The
authors suggest relationships between generalized anxi-
ety and reduced pallidal inhibition of thalamofronto-
temporal projections, and between panic attacks and
pathological changes in locus ceruleus function.
Obsessive-compulsive disorder has been linked to basal
ganglia pathology,
36 which may also produce disruption
of frontal circuitry. It would thus be expected that
increased rates of obsessive and compulsive symptoms
may occur at increased rates in PD.In a study of 30 PD
patients,Tomer et al
37 found that severity of left-sided
motor symptoms correlated significantly with increases
in overconscientiousness,repetition,disturbing thoughts,
and cleanliness obsessions.Increases in concern regard-
ing routine and orderliness were the only obsessive and
compulsive symptoms highly correlated with right-sided
motor symptom severity. Severity of depressive symp-
toms did not show a correlation with side of motor symp-
tom presence. Since greater deficiencies in striatal
dopamine function have been seen contralateral to the
side of worse motor function in PD,the authors suggest
that neurodegeneration of the dopamine system may
contribute to development of obsessive and compulsive
symptoms in PD.Alegret et al
38 found that PD patients
with more severe motor symptoms showed more obses-
sive traits and admitted to more checking,doubting,and
cleaning behaviors than age-matched normal controls,as
opposed to those with milder disease,suggesting that a
certain degree of basal ganglia pathology is needed to
generate these symptoms.
There have been no studies to date on treatment of anx-
iety disorders in PD.As with depression in PD,treatment
generally proceeds as it would for any elderly person
with an anxiety disorder, with extra caution regarding
side effects and drug interactions.SSRIs are generally the
first type of medication administered.Benzodiazepines
may be helpful for treatment of anxiety symptoms,espe-
cially until another medication,eg,an SSRI,has time to
take effect.However,benzodiazepines may impair cog-
nition,especially in PD patients with dementia,and ben-
zodiazepine withdrawal may precipitate anxiety.
Hallucinations and psychosis
Psychosis in PD that requires antipsychotic therapy is fre-
quently associated with severe morbidity,including nurs-
ing home placement and persistent psychotic symptoms.
The prevalence of hallucinations and psychosis in PD has
increased substantially with the use of levodopa treatment
for motor symptoms.Their presence has also been found
to increase the risk of death in PD.Factor et al report that
the use of atypical antipsychotic therapy has apparently
reduced some of morbidity and mortality associated with
PD psychosis,on the basis of the finding that 28% of nurs-
ing home patients died within 2 years of admission com-
pared with 100% in a study conducted prior to availabil-
ity of atypicals;however,psychosis remains a significant
problem in the treatment of PD.
39 Between 20% and 40%
of PD patients will experience these symptoms at some
point during the course of the illness.
40
Hallucinations in PD can be very vivid,and accompanied
by either preserved insight, which is not a state of psy-
chosis,or diminished insight,constituting actual psychosis.
In clinical practice,a continuum of insight is seen,a find-
ing that is supported by research.
41Visual hallucinations
are the most common type of hallucination in PD
patients.
42,43 People,animals,or objects are often reported,
and some patients are amused by these manifestations.
The figures disappear when the patient attempts to touch
them.A study of 102 consecutive clinic patients diagnosed
with PD using strict criteria found that almost 30% had
visual hallucinations or delusions.Symptoms in four of the
patients were found to be secondary to delirium.
41 Some
data suggest that the presence of visual hallucinations is
stable over time.
44A large,community-based study of PD
patients found certain features associated with increased
risk for hallucinations,including advanced age,later stage
of PD,cognitive impairment,and depression.
45
The causal role of dopaminergic treatment agents with
respect to these symptoms is somewhat controversial.
Psychosis and hallucinations were seen in PD prior to the
development of dopaminergic agents,but the prevalence
of these symptoms has increased dramatically with the
use of such treatments.Most groups feel that dopamin-
ergic therapy for the motor symptoms of PD causes the
majority of hallucinations and psychosis seen in PD,per-
haps by overstimulation of the mesocorticolimbic
dopamine system, which may be oversensitive in PD.
46
Friedman and Sienkiewicz
47 found that patients who have
an earlier onset of PD have more complex psychotic
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likely to develop dyskinesias as a side effect of treatment.
The authors suggest that this may be due to the more
focal nature of the pathology in young-onset PD patients,
where neuropathological change may be primarily in the
dopaminergic system.
48
Some investigators feel the underlying disarray of the
dopaminergic system in PD itself contributes more to
development of hallucinations and psychosis.Two large
studies did not find an association between the use of
antiparkinsonian medications and the presence of hallu-
cinations,suggesting the underlying disease pathology is
the more important factor.
41,45 Holroyd et al
41 proposed
that visual system abnormalities may play a role in devel-
opment of hallucinations in many patients.
If the patient is not disturbed by the hallucinations and has
preserved insight,no treatment may be needed.Treatment
of hallucinations and psychosis generally begins with a
careful evaluation of the patient to ensure that underlying
infection or interaction of medications is not producing
delirium with psychosis.Once delirium has been ruled out,
antiparkinsonian medication dosage should be reduced,if
this is possible without significant worsening of motor
function,since this may reduce the severity of hallucina-
tions.Many patients develop their own coping strategies
for these symptoms. Diederich et al
49 found that almost
80% of PD patients with hallucinations used coping strate-
gies including cognitive techniques,interactive techniques,
and visual techniques (69%, 62%, and 33% of patients
used these strategies,respectively).
If pharmacotherapy is required,atypical antipsychotics
are most commonly used,since they are the least likely
to cause side effects or worsen motor symptoms.At this
time,the atypical neuroleptic quetiapine is the first-line
treatment used by most clinicians to treat hallucinations
or psychosis in PD.Dewey and O’Suilleabhain
50 reported
an overall favorable response rate of 66% in 61 PD
patients with drug-induced psychosis in a retrospective
study.Targum and Abbot
51 found quetiapine to be effi-
cacious and well tolerated in an open-label study of 11
PD patients with hallucinations and psychosis.Low doses
(12.5 mg/day quetiapine may be sufficient in some
patients) should be tried to minimize side effects,since
there have been case reports of motor symptom exacer-
bation with quetiapine treatment.
52
Clozapine, an atypical antipsychotic agent, is the most
widely studied medication used for treatment of halluci-
nations and delusions in PD.In a large,randomized,dou-
ble-blind,placebo-controlled study of low-dose clozap-
ine for hallucinations and psychosis,patients in the med-
ication group showed significant improvement in psy-
chiatric symptoms.Clozapine was also found in this study
to improve tremor, and did not worsen parkinsonian
symptoms.
53The main drawback of clozapine use is the
need for frequent blood draws,due to the risk of med-
ication-induced leukopenia,which can be fatal.
Two other atypical neuroleptics,olanzapine and risperi-
done,have shown some efficacy in treatment of halluci-
nations and psychosis in PD. However, both have also
been reported to worsen motor symptoms.
54-56 The one
double-blind, randomized study comparing olanzapine
and clozapine in hallucinating PD patients was stopped
after a significant decline in motor function was seen in the
olanzapine-treated patients.The authors of this study rec-
ommended that olanzapine not be used for PD patients.
57
A single case report by Connemann and Schonfeldt-
Lecuona
58 found remission of psychosis and improvement
of motor symptoms in a PD patient treated with ziprasi-
done, a new atypical antipsychotic. However, another
report described development of neuroleptic malignant
syndrome in a PD patient who was being treated with
ziprasidone.
59These are the only reports of ziprasidone use
in patients with PD to date; further study is needed to
determine its safety and efficacy in this population.
Cognitive impairment and dementia
Specific cognitive deficits have been described in early PD.
Studies using strict criteria for dementia show prevalence
estimates ranging from approximately 18% to 41% in
community-based samples.
60-64 Dementia in PD is different
from that seen in Alzheimer’s disease (AD) in several
ways. PD patients have more pronounced executive
deficits (such as difficulties in planning and set-switching)
and motivational decline than in early AD patients.
65 Many
patients with PD have slowed thinking and mild impair-
ment of executive function, but do not develop actual
dementia,even in advanced stages of PD.
66 Even in cases
where cognitive impairment does not lead to dementia,
these changes in the ability to plan and execute tasks can
be extremely disabling to many patients,especially if they
wish to continue to work despite progression of motor
symptoms. Family members and other caregivers may
become frustrated with a patient’s lack of motivation and
inability to follow through on plans.Education of patients
and families as to what apathy and impaired executive
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as PD,which is regarded by the general public as simply a
disorder of motor function,can be a meaningful interven-
tion in many cases.Formal neuropsychological tests of cog-
nitive function can help differentiate dementia due to PD
from other dementias,such as AD,in a patient who has PD
and cognitive changes.
When evaluating a PD patient with possible dementia,
there are numerous factors that may contribute to wors-
ening of cognition.These include factors specific to PD,
such as toxicity of PD medications for the movement dis-
order.Other causes are seen throughout the geriatric pop-
ulation,including polypharmacy and delirium (Table II).
Addressing these issues may help reduce the severity of
dementia and lessen disability due to cognitive factors in
the patient. The most commonly cited risk factors for
development of dementia in PD include advancing age
and severity of extrapyramidal signs.Recent work suggests
that this may be due to a combination of the effect of age
and extrapyramidal signs,rather than separate effects.
67
The neuropathology underlying dementia in PD is unclear.
Neuronal dysfunction due to PD itself may cause memory
loss.However,some patients with PD and memory decline
also have changes that are more consistent with neu-
ropathological findings seen in AD.Many PD patients have
a mix of the two types of pathology.
68,69 Deficits in the
dopaminergic system contribute to cognitive decline,but
involvement of the cholinergic and adrenergic systems is
also likely. PD autopsy studies have shown significant
reductions in neocortical cholinergic neurons.
70
Although functional imaging has been used to study
motor changes in PD,little work has been done to exam-
ine cognitive deficits, despite the high frequency of this
symptom in PD.As discussed above,executive dysfunc-
tion,including problems with planning and set switching,
are common in PD.Some groups have used modified ver-
sions of the Tower of London,a planning task,to examine
executive performance with functional imaging,and found
variable dorsolateral prefrontal activation changes in
PD.
71,72 Lewis et al
73 examined early cognitive changes in
PD and found reduced activity in frontostriatal circuits
during performance of a working memory task.
Cholinesterase inhibitors have received the most attention
as potential agents to treat PD dementia.The medications
discussed below,donepezil,rivastigmine,galantamine,and
memantine (an N-methyl-D-aspartate [NMDA] antago-
nist),are all approved for use in treatment of AD in the
US,but not for use in other types of dementia,including
that associated with PD.Donepezil has received the most
extensive study as a potential therapeutic agent for
dementia in PD.Aarsland et al
74 performed a double-blind,
placebo-controlled, crossover study and found that this
medication was well tolerated in PD patients and did not
worsen motor symptoms. Significant positive effects of
donepezil treatment on cognition were seen on objective
memory testing and on clinician and caregiver ratings.
Open-label studies also suggest donepezil may be useful
in the treatment of hallucinations in PD,but worsening of
motor symptoms and delusions have been reported in
these studies.
75,76 In addition to possibly improving cogni-
tion, rivastigmine has also been found to ameliorate 
hallucinations and improve behavioral problems.
77,78
Galantamine,a cholinesterase inhibitor with additional
nicotinic activity approved for use in AD,has been inves-
tigated for use in PD dementia,with some positive pre-
liminary results,but variable effects on motor function.
79
Donepezil,rivastigmine,and galantamine may all poten-
tially worsen motor function in PD.
Behavioral symptoms,such as hallucinations,may improve
with cholinesterase inhibitor treatment, as has been
reported in some AD cases treated with these agents.
Contraindications to acetylcholinesterase inhibitor use
include a history of bleeding gastric ulcers, since these
medications will increase gastric secretions.Nonsteroidal
anti-inflammatory drugs (NSAIDs) may increase the risk
of peptic ulcer or gastrointestinal bleeding when taken
with cholinesterase inhibitors.Gastrointestinal side effects,
such as nausea and diarrhea,are common,but often tran-
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Table II. Factors that may contribute to cognitive impairment and demen-
tia in patients with Parkinson’s disease (PD). REM, rapid eye
movement.
Factors specific to PD
• Toxicity of dopaminergic agents
• Hallucinations, psychosis, or delirium secondary to
antiparkinsonian medications
• Exacerbation of cognitive dysfunction during medication
“off” periods
• Sleep deprivation (due to sleep fragmentation in PD, REM
sleep disorder, vivid nightmares)
Factors common in geriatric patients in general
• Medication interactions
• Use of anticholinergic agents, or agents with high levels of
anticholinergic activity
• Undiagnosed depression or other mood disorder
• Other psychiatric symptoms (eg, anxiety)sient side effects.Cardiac conduction abnormalities may
occur,due to vagotonic effects on the sinoatrial and atrio-
ventricular nodes.Cholinesterase inhibitors are likely to
exaggerate succinylcholine-type muscle relaxation during
anesthesia due to anticholinesterase properties.
Three studies have used memantine,a moderate-affinity
NMDA antagonist,to treat motor symptoms in PD,includ-
ing an early study of intravenous administration.
80-82These
results suggest there are some beneficial effects with
respect to PD motor symptoms;however,there were side
effects, including behavioral changes. Further work is
needed to determine safety and efficacy of this agent for
treatment of both cognitive and motor symptoms in PD.
Neuroprotective agents,which are being studied for pre-
vention of dementia in various neurodegenerative ill-
nesses,are being tested for use in PD.
83,84
DBS and behavioral changes
There is increasing recognition that deep brain stimulation
(DBS) and other surgical interventions for motor symp-
toms of PD may have additional effects on behavior.The
basic premise of DBS is that neuropathological change in
PD leads to abnormal neural transmission from several
structures,including the subthalamic nucleus and globus
pallidus internus.DBS interrupts this aberrant activity,and
ameliorates motor symptoms of PD.Given that frontal-
subcortical circuits are known to affect behavior,
85 in addi-
tion to their modulation of movement,it is important that
patients are evaluated for behavioral symptoms prior to
surgery,and that potential postoperative changes in psy-
chiatric or cognitive status are addressed quickly.Possible
negative effects of DBS on a patient’s emotional state and
cognition should be considered along with other potential
surgical complications of DBS.
Depression and depressed mood, the most commonly
seen psychiatric symptoms in PD,have received the most
study in DBS patients.Other behavioral changes,includ-
ing euphoric mood and frank mania,hallucinations,anx-
iety,and sleep disorders have also received some limited
study.
86The efficacy of DBS is being evaluated in refrac-
tory cases of obsessive-compulsive disorder,an approach
that may help illuminate the neurobiology underlying
both disorders,since similar frontostriatal circuitry may
be involved.
Rates of depressed mood associated with DBS vary
widely,from less than 10% to over 30% of patients expe-
riencing these symptoms.
87-91The role of past psychiatric
history as a predictor of psychiatric outcome after DBS
is not definitive at this time,but there is some indication
from existing reports that patients with a prior history of
mood symptoms may be more likely to develop
depressed mood following DBS.
87,88,91 Suicidal ideation
and suicide have also been reported.
87,88,91 It should be
noted that many patients with prior history of depression
do not develop depressed mood associated with DBS.It
is thus advisable that patients receive psychiatric evalu-
ation prior to DBS,and that psychiatric conditions such
as depression and anxiety receive adequate treatment
preoperatively.
As with psychiatric symptoms, the reported effects of
DBS on cognition are variable.It is generally agreed that
patients should receive cognitive screening as part of pre-
operative evaluation, since there have been reports of
patients with poor cognitive function who became
demented following DBS.
92-94 In addition, DBS may be
particularly likely to contribute to cognitive deficits in
patients over age 69.
95Thus,the risks and benefits of the
procedure should be weighed with particular care in
these patients,for whom any further decline in cognition
could greatly offset improvement of motor symptoms
with DBS.
Conclusion
As we further our understanding of the neuropsychiatric
symptoms in PD,treatment of these patients has become
more challenging.Although many agents are now avail-
able to treat motor symptoms in PD,less is known about
safety and efficacy of treatment for behavioral symptoms,
despite the fact that they affect large numbers of patients
and significantly contribute to morbidity and mortality in
many cases.A multitude of psychiatric symptoms is seen
in PD,including mood changes,anxiety disorders,halluci-
nations,and frank psychosis.Changes in cognitive function
are also seen,and,in some cases,progress to development
of dementia.Treatment of these behavioral symptoms can
greatly improve patients’ overall function and reduce the
burden placed on caregivers.Thus,despite the lack of for-
mal treatment studies, clinicians should make efforts to
treat behavioral disturbances.Surgical interventions,such
as DBS,are extremely beneficial for treatment of motor
symptoms,but may worsen or cause behavioral symptoms.
Patients should be evaluated carefully before DBS proce-
dures and should also be monitored postoperatively for
development of behavioral changes. ❏
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Trastornos de conducta en la enfermedad de
Parkinson
El tratamiento de la enfermedad de Parkinson (EP)
es complejo y a menudo requiere evaluar los cam-
bios conductuales además de los trastornos del
movimiento. Los pacientes con EP pueden presen-
tar cualquier trastorno psiquiátrico que se dé en la
población general; y algunas enfermedades como
la depresión y los trastornos ansiosos pueden pro-
ducirse a partir de cambios neuropatológicos rela-
cionados con la EP. En muchos pacientes que son
tratados con agentes dopaminérgicos para los sín-
tomas motores se observan alucinaciones en rela-
ción con la medicación. También se ha observado
deterioro cognitivo el cual puede ser multifactorial.
El tratamiento de los síntomas conductuales en la
EP puede mejorar significativamente el funciona-
miento general del paciente y la calidad de vida. A
medida que las intervenciones quirúrgicas y la esti-
mulación cerebral profunda de los núcleos subtalá-
micos de la sustancia nigra están siendo aplicados
con mayor frecuencia para tratar los síntomas
motores, resulta necesario evaluar los efectos sobre
la conducta de estos procedimientos.
Troubles du comportement dans la maladie
de Parkinson
Le traitement de la maladie de Parkinson (MP) est
complexe et se doit souvent d’aborder les troubles
du comportement en plus des dyskinésies. Les
Parkinsoniens sont sujets aux mêmes troubles psy-
chiatriques que ceux observés dans la population
générale ; certains d’entre eux, comme la dépres-
sion ou l’anxiété, peuvent résulter de modifications
neuropathologiques liées à la MP. Des hallucina-
tions liées au traitement surviennent chez de nom-
breux patients parkinsoniens qui prennent un trai-
tement dopaminergique prescrit pour les troubles
moteurs. Un déficit cognitif est également observé
et peut être multifactoriel. Le traitement des trou-
bles du comportement dans la MP peut améliorer
de façon importante l’état général et la qualité de
vie des patients. Certaines interventions chirurgica-
les réalisées pour traiter les troubles moteurs, telle
la stimulation cérébrale profonde du noyau sous-
thalamique de la substance noire, sont de plus en
plus fréquentes et leurs effets sur le comportement
doivent être abordés.
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